Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* B-CLL~* Matutes score 4 or 5~* Binet stages B or C~* Age \> 65 years old~* No previous treatment of CLL by chemotherapy, radiotherapy or immunotherapy, except glucocorticoids \< 1 month~* Patient's written informed consent~* Life expectancy \> 6 months~Exclusion criteria~* Binet stage A~* ECOG performance status 2 or more~* Presence of a 17p deletion by FISH (\> 10% positive cores)~* Clinically significant auto-immune cytopenia, Coombs-positive hemolytic anemia as judged by the treating physician~* Patients with a history of another malignancy in complete remission less than 5 years, except basal cell skin cancer or tumor treated curatively by surgery~* Concomitant disease requiring prolonged use of corticosteroids (\> 1 month)~* Any severe co-morbidities such as NYHA Class III or IV heart failure, myocardial infarction within 6 months, unstable angina, ventricular tachyarrhythmias requiring ongoing treatment, severe uncontrolled myocardiopathy, uncontrolled hypertension, severe chronic obstructive pulmonary disease with hypoxemia, or uncontrolled diabetes mellitus.~* CIRS (Cumulative Illness rating Scale) \> 6~* Known hypersensitivity to murine proteins or to any of the study drugs or to their components~* Transformation into an aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin lymphoma) or prolymphocytic leukemia~* Active bacterial, viral or fungal infection~* Seropositivity HIV, hepatitis C or hepatitis B (unless clearly due to vaccination)~* Total bilirubin, alkaline phosphatases and aminotransferases \> 2 x ULN~* Creatinine clearance \< 60 ml/min calculated according to the formula of Cockcroft and Gault~* Any coexisting medical or psychological condition that would preclude participation to the required study procedures~* Patient with mental deficiency preventing proper understanding of the requirements of treatment~Inclusion criteria at randomization~* Patients having received the full induction phase with 4 FC and 6 rituximab courses (with/without dose adjustments as per protocol)~* Complete or partial response according to NCI and iwCLL criteria at the end of induction phase~* Recovery from FCR toxicities~* Patient willingness to continue on protocol

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): Observation every 8 weeks during 2 years
- rituximab arm (Type: EXPERIMENTAL): rituximab :500 mg/m² every 8 weeks during 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).